Fresenius Kabi announced the immediate availability of Potassium Phosphates Injection in 3 presentations: phosphorus 15mmol/5mL and potassium 22mEq/5mL in single-dose 5mL vials, phosphorus 45mmol/15mL and potassium 66mEq/15mL in single-dose 15mL vials, and phosphorus 150mmol/50mL and potassium 220mEq/50mL in 50mL pharmacy bulk package vials.
Potassium Phosphates Injection is indicated:
- As a source of phosphorus in intravenous (IV) fluids to correct hypophosphatemia in patients aged ≥12 years when oral or enteral replacement is not possible, insufficient or contraindicated.
- For parenteral nutrition in adults and pediatric patients aged ≥12 years when oral or enteral nutrition is not possible, insufficient or contraindicated
Potassium Phosphates Injection contains aluminum that may be toxic. Exposure to aluminum is not more than 1.4mcg/kg/day when patients are administered the recommended dosage.
“Fresenius Kabi is pleased to offer healthcare providers flexibility and choice with the introduction of 3 FDA-approved presentations of Potassium Phosphates Injection to support their clinical needs,” said John Ducker, president and CEO of Fresenius Kabi USA. “We are proud to continue to supply the widest array of Potassium Phosphates Injection dosage options among all NDA-approved suppliers.”
For more information visit fresenius-kabi.com.
This article originally appeared on MPR